A completely biological "off-the-shelf" arteriovenous graft that recellularizes in baboons

Zeeshan H Syedain, Melanie L Graham, Ty B Dunn, Timothy D O'Brien, Sandra L. Johnson, Robert J Schumacher, Robert T Tranquillo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Prosthetic arteriovenous grafts (AVGs) conventionally used for hemodialysis are associated with inferior primary patency rates and increased risk of infection compared with autogenous vein grafts. We tissue-engineered an AVG grown from neonatal human dermal fibroblasts entrapped in bovine fibrin gel that is then decellularized. This graft is both "off-the-shelf" (nonliving) and completely biological. Grafts that are 6 mm in diameter and about 15 cm in length were evaluated in a baboon model of hemodialysis access in an axillary-cephalic or axillarybrachial upper arm AVG construction procedure. Daily antiplatelet therapy was given. Grafts underwent both ultrasound assessment and cannulation at 1, 2, 3, and 6 months and were then explanted for analysis. Excluding grafts with cephalic vein outflow that rapidly clotted during development of the model, 3- and 6-month primary patency rates were 83% (5 of 6) and 60% (3 of 5), respectively. At explant, patent grafts were found to be extensively recellularized (including smoothelin-positive smooth muscle cells with a developing endothelium on the luminal surface). We observed no calcifications, loss of burst strength, or outflow stenosis, which are common failure modes of other graft materials. There was no overt immune response. We thus demonstrate the efficacy of an off-the-shelf AVG that is both acellular and completely biological.

Original languageEnglish (US)
Article numbereaan4209
JournalScience Translational Medicine
Volume9
Issue number414
DOIs
StatePublished - Nov 1 2017

Fingerprint

Papio
Transplants
Renal Dialysis
Veins
Head
Fibrin
Catheterization
Smooth Muscle Myocytes
Endothelium
Pathologic Constriction
Arm
Fibroblasts
Gels

Cite this

A completely biological "off-the-shelf" arteriovenous graft that recellularizes in baboons. / Syedain, Zeeshan H; Graham, Melanie L; Dunn, Ty B; O'Brien, Timothy D; Johnson, Sandra L.; Schumacher, Robert J; Tranquillo, Robert T.

In: Science Translational Medicine, Vol. 9, No. 414, eaan4209, 01.11.2017.

Research output: Contribution to journalArticle

@article{f6906869c8374131abd7a131764725fb,
title = "A completely biological {"}off-the-shelf{"} arteriovenous graft that recellularizes in baboons",
abstract = "Prosthetic arteriovenous grafts (AVGs) conventionally used for hemodialysis are associated with inferior primary patency rates and increased risk of infection compared with autogenous vein grafts. We tissue-engineered an AVG grown from neonatal human dermal fibroblasts entrapped in bovine fibrin gel that is then decellularized. This graft is both {"}off-the-shelf{"} (nonliving) and completely biological. Grafts that are 6 mm in diameter and about 15 cm in length were evaluated in a baboon model of hemodialysis access in an axillary-cephalic or axillarybrachial upper arm AVG construction procedure. Daily antiplatelet therapy was given. Grafts underwent both ultrasound assessment and cannulation at 1, 2, 3, and 6 months and were then explanted for analysis. Excluding grafts with cephalic vein outflow that rapidly clotted during development of the model, 3- and 6-month primary patency rates were 83{\%} (5 of 6) and 60{\%} (3 of 5), respectively. At explant, patent grafts were found to be extensively recellularized (including smoothelin-positive smooth muscle cells with a developing endothelium on the luminal surface). We observed no calcifications, loss of burst strength, or outflow stenosis, which are common failure modes of other graft materials. There was no overt immune response. We thus demonstrate the efficacy of an off-the-shelf AVG that is both acellular and completely biological.",
author = "Syedain, {Zeeshan H} and Graham, {Melanie L} and Dunn, {Ty B} and O'Brien, {Timothy D} and Johnson, {Sandra L.} and Schumacher, {Robert J} and Tranquillo, {Robert T}",
year = "2017",
month = "11",
day = "1",
doi = "10.1126/scitranslmed.aan4209",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "414",

}

TY - JOUR

T1 - A completely biological "off-the-shelf" arteriovenous graft that recellularizes in baboons

AU - Syedain, Zeeshan H

AU - Graham, Melanie L

AU - Dunn, Ty B

AU - O'Brien, Timothy D

AU - Johnson, Sandra L.

AU - Schumacher, Robert J

AU - Tranquillo, Robert T

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Prosthetic arteriovenous grafts (AVGs) conventionally used for hemodialysis are associated with inferior primary patency rates and increased risk of infection compared with autogenous vein grafts. We tissue-engineered an AVG grown from neonatal human dermal fibroblasts entrapped in bovine fibrin gel that is then decellularized. This graft is both "off-the-shelf" (nonliving) and completely biological. Grafts that are 6 mm in diameter and about 15 cm in length were evaluated in a baboon model of hemodialysis access in an axillary-cephalic or axillarybrachial upper arm AVG construction procedure. Daily antiplatelet therapy was given. Grafts underwent both ultrasound assessment and cannulation at 1, 2, 3, and 6 months and were then explanted for analysis. Excluding grafts with cephalic vein outflow that rapidly clotted during development of the model, 3- and 6-month primary patency rates were 83% (5 of 6) and 60% (3 of 5), respectively. At explant, patent grafts were found to be extensively recellularized (including smoothelin-positive smooth muscle cells with a developing endothelium on the luminal surface). We observed no calcifications, loss of burst strength, or outflow stenosis, which are common failure modes of other graft materials. There was no overt immune response. We thus demonstrate the efficacy of an off-the-shelf AVG that is both acellular and completely biological.

AB - Prosthetic arteriovenous grafts (AVGs) conventionally used for hemodialysis are associated with inferior primary patency rates and increased risk of infection compared with autogenous vein grafts. We tissue-engineered an AVG grown from neonatal human dermal fibroblasts entrapped in bovine fibrin gel that is then decellularized. This graft is both "off-the-shelf" (nonliving) and completely biological. Grafts that are 6 mm in diameter and about 15 cm in length were evaluated in a baboon model of hemodialysis access in an axillary-cephalic or axillarybrachial upper arm AVG construction procedure. Daily antiplatelet therapy was given. Grafts underwent both ultrasound assessment and cannulation at 1, 2, 3, and 6 months and were then explanted for analysis. Excluding grafts with cephalic vein outflow that rapidly clotted during development of the model, 3- and 6-month primary patency rates were 83% (5 of 6) and 60% (3 of 5), respectively. At explant, patent grafts were found to be extensively recellularized (including smoothelin-positive smooth muscle cells with a developing endothelium on the luminal surface). We observed no calcifications, loss of burst strength, or outflow stenosis, which are common failure modes of other graft materials. There was no overt immune response. We thus demonstrate the efficacy of an off-the-shelf AVG that is both acellular and completely biological.

UR - http://www.scopus.com/inward/record.url?scp=85032831624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032831624&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aan4209

DO - 10.1126/scitranslmed.aan4209

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 414

M1 - eaan4209

ER -